Clinical trials: Skin to Skin
glp1 Agonist, Gene Expression
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared…
- Conditions
- glp1 Agonist, Gene Expression, Skin Laxity
- Trial name
- NCT07224880
- Testing
- ellacor
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Cytrellis Biosystems, Inc.
Wrinkle, Scar
Pre-marketing Trial to Assess Safety and Efficacy of 'Volumizing Filler Based on Hyaluronic Acid and Recombinant Collagen'
Study to validate the safety and efficacy of the Hyaluronic Acid +Collagen filler 40 patients will undergo through 3 visits one to asses the health and apply the filler one after 4 weeks to check the results one after 16 weeks…
- Conditions
- Wrinkle, Scar, Laxity; Skin
- Trial name
- NCT06336044
- Testing
- Karisma
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Taumedika s.r.l.
Melanoma Metastatic, Melanoma of Skin
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Why the research is needed: Researchers are looking for a better way to treat melanoma that has spread or cannot be removed surgically.
- Conditions
- Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent
- Trial name
- NCT06784648
- Testing
- pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution)
- Where
- 4 sites in Germany, Spain and 1 more
- Volunteers
- 35 people
- Sponsor
- BioInvent International AB
Melanoma (Skin Cancer), Unresectable Melanoma
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
- Conditions
- Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT07288203
- Testing
- Lifileucel
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 24 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Skin Health
Evaluatation of a Microcurrent + Cold Therapy Device
The present study aims to assess use of a microcurrent and cryotherapy device on skin health over an 8-week period using an at-home device that provides 15-minutes of microcurrent + cold therapy once daily.
- Trial name
- NCT07510581
- Testing
- Acute Microcurrent Treatment, Acute Microcurrent + cold therapy, 8-week Chronic Use of Microcurrent + Cold Therapy
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Therabody, Inc.
Skin Ageing
Skin Mitochondrial Protection by R0090948A Active
The study intends to evaluate the skin longevity through mitochondria protection efficacy of cosmetic products after 3 months of product application, under UV exposures or not, followed by skin biopsies.
- Trial name
- NCT07853027
- Testing
- Skin biopsy
- Volunteers
- 13 people
- Sponsor
- L'Oreal
Sensitive Skin
Dermal Acceptability Evaluation in Sensitive Skin
The goal of this clinical trial is to evaluate the dermatological safety and acceptability of a cosmetic product in participants with sensitive skin.
- Trial name
- NCT07848347
- Testing
- moisturizing cream
- Where
- Brazil
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Oily Skin, Acne Prone Skin
Dermal and Ophthalmological Acceptability and Comedogenicity Assessment of a Cosmetic Product
The goal of this clinical trial is to evaluate the dermatological and ophthalmological safety of a cosmetic product and to assess its comedogenic and acnegenic potential in participants with oily or acne-prone skin.
- Trial name
- NCT07848555
- Testing
- moisturizing cream
- Where
- Brazil
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Brainfarma Industria Química e Farmacêutica S/A
Skin Aging, Skin Quality
AnteAGE Exosomes and PEARL Multiplier With Microneedling for Facial Skin Quality
This exploratory clinical study evaluated changes in facial skin quality following a series of mechanical microneedling treatments combined with topical AnteAGE Exosomes and PEARL Multiplier and a standardized AnteAGE homecare…
- Trial name
- NCT07849205
- Testing
- Mechanical microneedling, AnteAGE Exosomes and PEARL Multiplier, AnteAGE Homecare Regimen
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Cellese Inc.
Skin Aging, Facial Rhytides
AnteAGE Biosomes With Radiofrequency Microneedling for Facial Skin Rejuvenation
This prospective, randomized controlled study evaluated the efficacy and tolerability of AnteAGE Biosome Solution used in conjunction with facial radiofrequency microneedling.
- Conditions
- Skin Aging, Facial Rhytides, Skin Tone
- Trial name
- NCT07849556
- Testing
- AnteAGE Biosome Treatment Solution, Radiofrequency Microneedling, AnteAGE Homecare Regimen
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cellese Inc.
Facial Wrinkles, Skin Aging
Anti-Wrinkle Efficacy of a Syringic Acid-Containing Emulsion
This randomized, double-blind, split-face controlled study was conducted to evaluate the anti-wrinkle efficacy and safety of a Syringic acid-containing emulsion in healthy female subjects.
- Trial name
- NCT07850817
- Testing
- Synox-containing Emulsion, Control Emulsion
- Where
- South Korea
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- BioSpectrum Inc
ER-Positive HER2-Negative Breast Cancer
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of patients with hormone…
- Trial name
- SERENA-4 (NCT04711252)
- Testing
- AZD9833, Anastrozole, Palbociclib
- Where
- 263 sites in United States, Austria and 25 more
- Volunteers
- 1,371 people
- Sponsor
- AstraZeneca
Psoriasis
Psoriasis Longitudinal Assessment and Registry
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and guselkumab in patients with plaque and other forms of psoriasis.
- Trial name
- PSOLAR (NCT00508547)
- Where
- 320 sites in United States, Argentina and 20 more
- Volunteers
- 20,167 people
- Sponsor
- Janssen Scientific Affairs, LLC
Metastatic Melanoma, Unresectable Melanoma
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with…
- Conditions
- Metastatic Melanoma, Unresectable Melanoma, Melanoma
- Trial name
- NCT05727904
- Testing
- Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period
- Where
- 82 sites in United States, Australia and 14 more
- Volunteers
- 670 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer
Pan-tumor MRD Study
The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors.
- Conditions
- Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer, Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma, Melanoma (Skin Cancer)
- Trial name
- NCT06605404
- Testing
- blood and tissue samples
- Where
- 47 sites in United States
- Volunteers
- 1,350 people
- Sponsor
- Paradigm Health
Skin Inflammation, Cosmetic Skin
35 kDa Hyaluronan Fragment (HA35) Reduces Chronic Inflammation of Skin
To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems.
- Trial name
- NCT06387212
- Testing
- 35 kDa hyaluronan fragment HA35 injection
- Where
- Mongolia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Nakhia Impex LLC
Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation
Efficacy and Safety of High-Dose Oral 35 kDa Hyaluronan for Aesthetic Improvement
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of high-dose oral 70 kDa hyaluronan (HA35) for aesthetic improvement.
- Conditions
- Facial Subcutaneous Fullness, Subcutaneous Fat Accumulation, Facial Inflammatory Erythema, Dull Skin
- Trial name
- HA35-ORAL (NCT07583108)
- Testing
- High-Dose Oral 35 kDa Hyaluronan (HA35)
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Nakhia Impex LLC
Facial Subcutaneous Fat, Facial Erythema
Efficacy and Safety of Overnight Occlusive HA35 Gel for Facial Aesthetic Improvement
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of overnight occlusive topical application of 10% high-concentration 35 kDa hyaluronan (HA35) gel for facial aesthetic…
- Conditions
- Facial Subcutaneous Fat, Facial Erythema, Skin Dullness, Nasal Alar Pore Enlargement
- Trial name
- HA35-FACIAL (NCT07584811)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Facial Occlusive Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC
Dercum's Disease
A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas
This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
- Trial name
- NCT06303570
- Testing
- CBL-514 injection, 0.9% Sodium chloride
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Caliway Biopharmaceuticals Co., Ltd.
Skin Pruritus, Itch
Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus…
- Conditions
- Skin Pruritus, Itch, Eczema Itch, Neurodermatitis
- Trial name
- HA35-ITCH (NCT07580911)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC